Neutropenia after myeloablative conditioning regimens in cord blood transplant (CBT) recipients or following intensive chemotherapy for leukemia is associated with a high mortality risk from infectious complications necessitating interventions to reduce this neutropenic period. 1, 2 Several ex vivo expansion approaches have been identified that are capable of generating short-term hematopoietic repopulating cells derived from cord blood (CB) hematopoietic stem/progenitor cells (HSPC) that provide a myeloid bridge until hematopoietic reconstitution occurs. [3] [4] [5] [6] [7] [8] [9] However, these have relied on real-time expansion of partially human leukocyte antigen (HLA)-matched units with costs of the unit and manufacturing prohibitive for widespread use. Generating greater number of HSPC per starting cell than is currently achieved will be required to develop a cryopreserved product able to overcome HLA-matching barriers, thereby making it readily and widely available. Similar to models of leukemic cell self-renewal, we have undertaken a rational approach to maximize proliferation and inhibit differentiation to enhance generation of HSPC. We previously demonstrated that culture of CD34 þ CB HSPC in the presence of Delta1
Ext-IgG and growth factors results in a 16-fold increase in severe combined immunodeficiency (SCID)-repopulating cells (SRCs). 5 Likewise, Boitano et al. 3 described an aryl
Accepted article preview online 6 June 2014; advance online publication, Ext-IgG (5 mg/ml) to culture with SR1 significantly decreased the generation of TNC as compared with SR1 alone (Po0.05, Figure 1a ) with a trend toward decreased CD34 Ext-IgG (2.5 mg/ml), SR1 (750 nM) or the combination (SR1 750 nM, Delta1
Ext-IgG 5 mg/ml). TNC number was significantly decreased with Delta1 Ext-IgG with or without SR1 as compared with SR1 alone (Po0.05 and P ¼ 0.004, respectively). CD34 þ cell number generated was significantly decreased in culture with Delta1 Ext-IgG as compared with SR1 alone (P ¼ 0.004) and approached significance when the combination was compared with SR1 alone (P ¼ 0.17). Greater numbers of CD34 þ CD38 À CD90 þ cells 11 were generated when Delta1 Ext-IgG was added to the culture with SR1 as compared with culture with either Delta1 Ext-IgG or SR1 alone (P ¼ 0.05 and P ¼ 0.14, respectively). Results represent five independent experiments as mean ± s.e.m. Statistical analysis was performed using two-tailed, unpaired t-test. (b) The proportion of CD34 þ CD38 À CD90 þ cells in culture with the combination as compared with Delta1
Ext-IgG was equivalent (P ¼ 0.33) but both were significantly greater than that seen in cultures containing SR1 (P ¼ 0.04 and P ¼ 0.02, respectively). Relatively greater percent of more mature CMP ( 11, 12 populations were observed in culture with SR1 alone as compared with Delta1
Ext-IgG or Delta1
Ext-IgG and SR1 in combination (P ¼ 0.03 and P ¼ 0.07, respectively). Results represent five independent experiments as mean ± s.e.m. Statistical analysis was performed using two-tailed, unpaired t-test. (c) HES1 expression was assessed by quantitative PCR after cells were cultured for 6 h on IgG, Delta1
Ext-IgG , SR1, or Delta1 Ext-IgG and SR1 in combination. HES1 expression was normalized to house-keeping gene GUSB. HES1 expression level was 3.5-fold higher in the Delta1
Ext-IgG groups as compared with IgG control (P ¼ 0.0001) and 4.5-fold higher than SR1 alone (Po0.0001). HES1 expression level when Delta1
Ext-IgG was added to culture with SR1 was nearly 3.5-fold higher than in culture with SR1 alone (P ¼ 0.0002). Cells cultured with Delta1
Ext-IgG alone had greater HES1 expression levels than cells cultured in the combination (P ¼ 0.0035). Results represent three independent experiments as mean±s.e.m. Statistical analysis was performed using two-tailed, unpaired t-test.
þ CB HSPC (1 Â 10 4 ) were cultured overnight in the presence of IgG (5 mg/ml) with or without SR1 (750 nM) and transduced the following day with wild-type HES1 or control with a multiplicity of infection of 25. On day 6 of culture, CB HSPC were sorted for GFP using BD FACSAria cell sorter. After 14 days in culture, GFP-expressing cells were assessed for numbers of the least mature CD34 þ CD38 À CD90 lo HSPC. There was a 2.5-fold increase in the number of least mature HSPC generated when SR1 was added to culture with HES1-transduced HSPC (P ¼ 0.08). Culture of HES1-transduced cells in the presence of SR1 generated 25-fold more CD34 þ CD38 À CD90 lo HSPC than cells transduced with lenti-control (P ¼ 0.02). Results represent two independent experiments as mean ± s.e.m. Statistical analysis was performed using two-tailed, unpaired t-test. Figure 1a) . However, greater numbers of the least mature CD34 þ CD38 À CD90 lo population 11 were generated when Delta1
Ext-IgG was present in cultures with SR1 compared with Delta1
Ext-IgG alone (P ¼ 0.05) with a trend toward greater numbers compared with SR1 alone (P ¼ 0.14, Figure 1a) . Analysis of CD34 þ CD38 À CD90 lo , common myeloid progenitor (CMP) and granulocyte-monocyte and megakaryocyte-erythrocyte progenitor (GMP/MEP) cells 12 ( Figure 1b) revealed that the proportion of CD34 þ CD38 À CD90 lo cells in cultures with Delta1 Ext-IgG and SR1 was equivalent to the proportion in cultures with Delta1
Ext-IgG alone (P ¼ 0.33); however, both were significantly greater than in cultures with SR1 alone (P ¼ 0.04 and P ¼ 0.02, respectively). In contrast, there was a relatively greater percent of more mature CMP and GMP/MEP cells in culture with SR1 alone as compared with Delta1
Ext-IgG with or without SR1 (P ¼ 0.07 and P ¼ 0.03, respectively), suggesting that Delta1 Ext-IgG is further delaying myeloid differentiation resulting in enhanced generation of the least mature progenitors.
We next determined whether induction of HES1 in cells cultured in the presence of Delta1
Ext-IgG accounted, at least in part, for the ability of Delta1
Ext-IgG to enhance SR1-induced effects on expansion of HSPC. HES1 expression level was found to be 3.5-fold higher in cultures with Delta1
Ext-IgG alone compared with IgG control and over 4.5-fold greater than SR1 alone (Figure 1c) . When Delta1
Ext-IgG was added to cultures with SR1, HES1 induction was nearly 3.5-fold greater than SR1 alone, suggesting that Delta1
Ext-IgG induces HES1 expression in cells cultured with SR1 and this increase may be responsible at least in part for the delay in differentiation and enhanced early precursor generation seen in these cultures. Interestingly, cells cultured with Ext-IgG 2.5 mg/ml, IgG 2.5 mg/ml with SR1 or the combination with Delta1 Ext-IgG 5 mg/ml. The cultured progeny of 10 000 starting CD34 þ cells were transplanted into NSG mice, and early and late repopulating capability assessed at 2 weeks by bone marrow aspirates and 12-14 weeks by bone marrow harvests. (a) Early myeloid (percent CD45 þ CD33 þ ), (b) progenitor (percent CD45 þ CD34 þ ) and (c) more immature progenitor (percent CD45 þ CD34 þ CD33 À ) populations were assessed. For limiting dilution transplant (a), mice were injected with the cultured progeny of 1000, 4000 or 20 000 CD34 þ cells and bone marrow aspirates performed at 2 weeks. Two engraftment cutoffs were chosen based on percent engraftment observed in nonlimiting transplantation studies. The frequency of SRC was determined by the method of maximum likelihood with L-CALC software (StemCell Technologies) from the proportions of engrafted recipients. (d) All groups demonstrated multilineage engraftment with longer-term primary transplantation with enhanced total human and B-lymphoid (percent CD45 þ CD19 þ CD33 À ) engraftment in the combination group. All P-values represent unpaired, two-tailed ttests and are displayed on graphs with lines denoting comparisons. Results shown represent four independent experiments. Dots represent individual mice and lines represents mean engraftment.
Delta1
Ext-IgG alone had significantly greater HES1 expression as compared with those cultured in the combination (P ¼ 0.0035), possibly due to downregulation of HES1 expression through AhR antagonism as AhR has been shown to upregulate HES1 expression. 13 On the basis of ex vivo studies of murine progenitors demonstrating that overexpression of Hes1 inhibits myeloid differentiation and enhances generation of multipotent progenitor cells, 14 we determined whether HES1 overexpression in CB HSPC combined with SR1 might phenocopy effects of combining Delta1
Ext-IgG with SR1. We found 5-fold higher HES1 expression in HES1-transduced cells cultured on IgG as compared with control-transduced cells and 2-fold higher expression for HES1 overexpressing cells as compared with control-infected cells in the presence of SR1 (data not shown). Importantly, culture of HES1-transduced cells in the presence of SR1 generated 25-fold more CD34
þ CD38 À CD90 lo cells than culture with cells transduced with lenti-control and SR1 (Figure 1d ). To further illuminate the mechanism whereby HES1 expression affects culture with SR1, we attempted to abrogate HES1 expression through short hairpin (sh)RNA in CB HSPC cultured in the presence of Delta1
Ext-IgG , SR1 or the combination; however, despite green fluorescent protein (GFP) expression consistent with successful transduction of shRNA constructs, HES1 expression was unchanged as compared with control cultures.
We next determined the functional significance of CB HSPC generated in the presence of Delta1
Ext-IgG and/or SR1 by assessing their in vivo repopulating capability in immune-deficient NSG mice. We found significantly enhanced rapid myeloid reconstitution 2 weeks after transplantation from cells cultured with the combination in comparison with either factor alone (Figure 2a) . Limiting dilution transplants revealed a significant nearly 3-fold increase in frequency of RRCs able to reconstitute CD33 þ myeloid cells in mice that received cells cultured in the presence of Delta1
Ext-IgG and SR1 as compared with either alone based on robust, 45% marrow repopulation that is nearly completely myeloid at this early time post engraftment (Figure 2a ). At a more limiting level of marrow repopulation (1%), we also found a significant 3-fold difference between cells cultured with SR1 alone and the combination. However, the 1.5-fold difference found between cells cultured with Delta1
Ext-IgG alone or in the presence of Delta1
Ext-IgG and SR1 was not statistically significant; suggesting that the difference in RRC frequency between SR1 and Delta1
Ext-IgG at a more robust (5%) versus less robust (1%) level of marrow repopulation may reflect generation of less mature precursors with greater proliferative potential. Consistent with this hypothesis, the percent of CD34 þ progenitor cells present in the marrow was also significantly greater due to transplantation of cells cultured with both Delta1
Ext-IgG and SR1 compared with SR1 or Delta1
Ext-IgG alone (Figure 2b ). Further analysis revealed that a higher proportion of the CD34 þ cells in the marrow reconstituted with cells cultured with SR1 and Delta1
Ext-IgG were CD33 À compared with those derived from cultures containing SR1 or Delta1
Ext-IgG alone (Figure 2c) , further suggesting the more primitive nature of the precursors generated by SR1 and Delta1
Ext-IgG . Of note, rapid repopulation by B-lymphoid cells (percent CD45 þ CD33 À CD19 þ ) was significantly enhanced by cells cultured in the presence of SR1 alone in comparison with cells cultured with Delta1
Ext-IgG ±SR1 (data not shown). This may be a result of Notch1-mediated inhibition of the differentiation of multipotent precursors combined with enhanced generation of immature B cells due to AhR inhibition as suggested by the findings in AhR receptor-null mice. 15 Evaluation of longer-term repopulation at 12-14 weeks revealed multilineage engraftment in all groups (Figure 2d ). Although overall human engraftment was higher due to cells cultured with Delta1
Ext-IgG alone (Figure 2d) , this was primarily due to enhanced B-lymphoid engraftment (Figure 2d ). It is not clear whether these lymphoid cells were newly derived or represented longer-lived cells developed during earlier time points. While low-level CD3
þ engraftment was present in all groups at this later time point, it constituted o0.6% of total marrow engraftment and was not significantly different between the groups (data not shown). However, it is not known whether differences in engraftment would have been discerned in the presence of human thymic explants in NSG mice. Following secondary transplantation, no differences were found between the groups (average CD45 þ 0.22% in Delta1
Ext-IgG , 0.11% in SR1 and 0.18% in the combination, data not shown) demonstrating all three culture conditions generate similar long-term engrafting cells.
Our data indicate that the addition of Delta1 Ext-IgG to SR1 enhances the generation of more robust, RRCs. Given the fixed collection volume and cellular yield obtained from an individual CB unit, the ability to generate greater numbers of HSPC from a given CB unit without increasing the utilization of culture media, cytokines or other costly materials further allows development of cost-effective HSPC expansion methodologies. Moreover, generation of greater numbers of HSPC than currently achieved has the potential to make use of the large inventory of CB units currently too small for clinical application. This will be critical when developing cellular therapy for treating neutropenia outside of the CBT setting.
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Effects of the small-molecule inhibitor of integrin a4, TBC3486, on pre-B-ALL cells The treatment of patients with chemotherapy-resistant leukemia remains a challenge. A role of the microenvironment for drug resistance of leukemia cells has been proposed. 1 We have identified the adhesion molecule integrin a4 as a central mediator of drug resistance of pre-B-cell acute lymphoblastic leukemia (ALL). 2 We thus demonstrated that chemotherapyresistant pre-B-ALL cells can be eradicated in a xenograft model by concurrent blockade of a4 using natalizumab, a humanized anti-a4 antibody in clinical use against multiple sclerosis, 3 and Crohn's Disease. 2 Here, we extended our studies to an alternative a4 inhibitor, the non-peptidic small molecule TBC3486. Previous in vitro assays and molecular modeling studies indicated that TBC3486 behaves as a ligand mimetic, competing with VCAM-1 for the MIDAS site of integrin a4. 4 As such, the compound has shown efficacy in integrin a4-dependent models of inflammatory and autoimmune disease 4 and has shown efficacy in mice with autoimmune encephalomyelitis, a model for multiple sclerosis. 5 As opposed to natalizumab, which will inhibit both members of the a4 integrin family, a4b1 and a4b7, TBC3486 is 200-fold more potent in inhibiting a4b1 than a4b7. In addition, it is completely inactive against all other integrins tested, including members of the b2, b3 as well as other members of the b1 family of integrins. 4 The potential usefulness of this novel inhibitor for pre-B-ALL treatment was tested in our established in vitro and in vivo assays. 2, 4 We evaluated the effect of TBC3486 on de-adhesion of patient-derived ALL cells (LAX7R) using established adhesion assays. As a control for our studies, a close structural analog was used that lacks activity toward a4b1 integrin (THI0012). After activating LAX7R cells with 1 mM Mn 2 þ , leukemia cells were cocultured with the murine stromal cell line OP9. 6, 7 Subsequently, LAX7R cells were treated with different doses of TBC3486 (5, 10 and 25 mM) and its control, THI0012 (5, 10 and 25 mM), for 4 days. TBC3486 dose-dependently inhibited adhesion of ALL cells (Figure 1a) , albeit the adhesion was not completely blocked. The dose of 25 mM was selected for subsequent studies. The concentrations of compound required for inhibition in these assays are higher than previously reported. 4 This is due to the fact that TB3486 is highly protein bound in the presence of 20% serum (used in these assays), which significantly reduces the amount of free compound available to bind to the integrin receptor. Next, we determined whether TBC3486 decreases binding of three xenograft cells derived from primary pre-B-ALL cases (LAX7R, ICN3 and SFO3) to the counter-receptor of a4 integrin, human VCAM-1. Adhesion assays were performed as previously described 4, 8, 9 by culturing ALL samples treated with TBC3486 (25 mM) or THI0012 (25 mM) on hVCAM-1-coated plates for 2 days. Compared with the control group, TBC3486-treated ALL cells showed significantly less adhesion to hVCAM-1 (Figures 1c, e and  g) ; however, the adhesion was not completely blocked. CD49d (MFI) is expressed with higher intensity in LAX7R compared with the other two samples (ICN3 and SFO3) (data not shown), which may explain why TBC3486 blocked a larger percentage of LAX7R adhesion to VCAM-1. In addition to blocking cell adhesion, TBC3486 treatment also specifically targeted the expression of integrin a4, but not integrin a5 and a6 (Figure 1b ). The treatment with TBC3486 did not affect cell viability in all three cases (Figures 1d, f and h ) compared with the THI0012 control. Taken together, TBC3486 leads to the partial de-adhesion of pre-B-ALL cells from its counter-receptor VCAM-1 under the conditions described.
We previously showed that antibody-mediated integrin a4 blockade can sensitize leukemia cells to chemotherapy. 2 Therefore, we evaluated whether TBC3486 can not only de-adhere cells from its counter-receptors but also sensitize them to chemotherapy. To study the drug sensitivity of human leukemia, ALL (LAX7R) cells were co-cultured with murine calvaria-derived OP9 stromal cells, which allow in vitro studies beyond 2 days. Then this co-culture was exposed to chemotherapy as previously described.
9,10 ALL cells were treated with chemotherapy (vincristine, dexamethasone, L-asparaginase; VDL) or saline as control for 4 days, with TBC3486 (25 mM) or control THI0012. TBC3486 with VDL treatment reduced the cell viability of human leukemia LAX7R (51 ± 1% vs 31 ± 1%; Po0.05) (Figure 2a ), ICN3 (60 ± 3% vs 49 ± 1%; Po0.05) (Figure 2b ) and SFO3 (78 ± 1% vs 65±1%; Po0.05) (Figure 2c ), indicating that this combination therapy sensitized leukemia cells to chemotherapy in vitro. Nevertheless, all chemoprotection afforded by OP9 cells was removed by TBC3486 in spite of only partial de-adhesion. This observation at least suggests that effects over and above adhesion and physical chemoprotection provided by stromal cells are mediated through a4 integrin.
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